Zevra Therapeutics’ (ZVRA) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Zevra Therapeutics (NASDAQ:ZVRA) in a research note released on Wednesday morning,Benzinga reports. The firm currently has a $20.00 target price on the stock.

A number of other research firms also recently commented on ZVRA. Canaccord Genuity Group cut their price objective on shares of Zevra Therapeutics from $25.00 to $23.00 and set a “buy” rating for the company in a report on Thursday, November 14th. Roth Mkm increased their price objective on shares of Zevra Therapeutics from $19.00 to $21.00 and gave the company a “buy” rating in a report on Tuesday, September 24th. JMP Securities assumed coverage on shares of Zevra Therapeutics in a report on Tuesday, September 24th. They issued an “outperform” rating and a $17.00 price objective for the company. Maxim Group raised their price target on shares of Zevra Therapeutics from $18.00 to $25.00 and gave the stock a “buy” rating in a report on Tuesday, September 24th. Finally, Guggenheim assumed coverage on shares of Zevra Therapeutics in a report on Monday, October 7th. They set a “buy” rating and a $20.00 price target for the company. Seven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Zevra Therapeutics has a consensus rating of “Buy” and a consensus price target of $21.00.

Zevra Therapeutics Price Performance

ZVRA opened at $8.97 on Wednesday. The company has a market cap of $478.78 million, a PE ratio of -4.64 and a beta of 1.93. The company has a quick ratio of 2.88, a current ratio of 2.88 and a debt-to-equity ratio of 0.84. Zevra Therapeutics has a twelve month low of $4.20 and a twelve month high of $9.27. The company has a 50-day moving average price of $8.09 and a 200 day moving average price of $6.57.

Zevra Therapeutics (NASDAQ:ZVRA) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.69) EPS for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.25). The business had revenue of $3.70 million during the quarter, compared to analyst estimates of $5.04 million. Zevra Therapeutics had a negative net margin of 342.63% and a negative return on equity of 159.54%. During the same quarter in the previous year, the company posted ($0.40) EPS. Sell-side analysts expect that Zevra Therapeutics will post -1.92 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Zevra Therapeutics

A number of hedge funds have recently made changes to their positions in the stock. FMR LLC boosted its position in shares of Zevra Therapeutics by 282,687.5% during the 3rd quarter. FMR LLC now owns 2,313,202 shares of the company’s stock worth $16,054,000 after purchasing an additional 2,312,384 shares during the period. Vanguard Group Inc. boosted its position in shares of Zevra Therapeutics by 3.6% during the 1st quarter. Vanguard Group Inc. now owns 1,704,006 shares of the company’s stock worth $9,883,000 after purchasing an additional 58,866 shares during the period. Geode Capital Management LLC boosted its position in shares of Zevra Therapeutics by 14.2% during the 3rd quarter. Geode Capital Management LLC now owns 1,043,864 shares of the company’s stock worth $7,246,000 after purchasing an additional 129,600 shares during the period. State Street Corp boosted its position in shares of Zevra Therapeutics by 7.4% during the 3rd quarter. State Street Corp now owns 772,825 shares of the company’s stock worth $5,363,000 after purchasing an additional 52,966 shares during the period. Finally, Stonepine Capital Management LLC purchased a new position in shares of Zevra Therapeutics during the 3rd quarter worth approximately $4,858,000. Hedge funds and other institutional investors own 35.03% of the company’s stock.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.